Skip to main content
Woman, living with factor XIII A-subunit deficiency, sitting next to her garden


Vanessa has congenital FXIII deficiency

Novo Nordisk can help your patients get the treatment and support they want

Novo Nordisk has a variety of resources and support to help your patients get the most out of their treatment with Tretten®


 



 

Help them get treatment

Patients with congenital FXIII A-subunit deficiency may be able to get help with treatment costs through Novo Nordisk’s Hemophilia and Rare Bleeding Disorder Product Assistance Programs.

Co-pay Assistance Program

Eligible patients receive up to $12,000/year toward their co-pay for a Novo Nordisk factor product.

Your patient may be eligible if they:

  • Have been prescribed a Novo Nordisk factor product
  • Are currently privately/commercially insured


 

Patient Assistance Program

Novo Nordisk provides factor products to qualifying patients at no charge.

Your patient may be eligible if they:

  • Have been prescribed a Novo Nordisk factor product
  • Are currently uninsured
  • Have no options for alternate coverage
  • Have a gap in coverage

Encourage such patients to submit a Product Assistance Program application or call 1-844-NOVOSEC (1-844-668-6732) to learn more.


 



 

Two ways to help them feel even more supported

NovoSecure™

NovoSecure™, the program that provides support to your patients, regardless of treatment choice.
 

Novo Nordisk Representatives

Your Tretten® patients have access to Novo Nordisk Representatives—excellent sources of information and support.


 


Selected Important Safety Information

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Indications and Usage

Tretten® (Coagulation Factor XIII A-Subunit [Recombinant]) is indicated for routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Tretten® is not for use in patients with congenital Factor XIII B-subunit deficiency.

Important Safety Information

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the exicipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Thromboembolic complications may occur. Monitor patients with conditions that predispose to thrombosis for signs and symptoms of thrombosis after administration of Tretten®.

Inhibitory antibodies may occur with Tretten®. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.

The most common adverse reactions reported in clinical trials (≥1%) were headache, pain in the extremities, pain at injection site, and increase in fibrin D dimer levels. 

Thrombosis may occur if Tretten® is administered concomitantly with Factor VIIa.

There are no adequate and well-controlled studies using Tretten® in pregnant women to determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Tretten®.

Please click here for Tretten® Prescribing Information.